

Adherium Attending American Thoracic Society (ATS) International Conference

Highlights:

- Adherium Executives will be joining more than 14,000 professionals in the fields of pulmonary, critical care, and sleep health for the 2024 American Thoracic Society (ATS) International Conference in San Diego, CA from 17-22 May 2024.
- Pulmonary clinicians and clinical researchers will be presenting the latest advances in pulmonary medicine during the Conference – an ideal setting to raise the profile of Adherium’s world-class Hailie® sensor and medication adherence technology.

Melbourne, Australia – 15 May 2024: Leading digital health company [Adherium Limited](#) (ASX:ADR) is pleased to announce key Company Executives will be attending the 2024 American Thoracic Society (ATS) International Conference in San Diego, CA from 17-22 May 2024.

This International Conference is one of the most highly regarded global respiratory health meetings, which showcases the latest advances in respiratory science, patient care, and global public health. It is expected to attract more than 14,000 professionals in the fields of pulmonary, critical care, and sleep health.

As a highlight, Adherium CEO Dr. Paul Mastoridis will be attending The Respiratory Innovation Summit, which connects leading innovators, investors, clinicians and advocacy groups who are dedicated to creating powerful new treatments for diseases of the lungs and airways. His primary goal will be to learn, network and raise the profile of Adherium’s Hailie® Smartinhaler® technology and cloud-based data collection portal on the ground.

Adherium CEO, Dr. Paul Mastoridis, said: *“I am delighted to be meeting with respected industry peers at the 2024 ATS International Conference. The time is now to raise awareness of the measured patient impact of our Hailie® Smartinhaler® technology – we have now achieved US reimbursement for Hailie® and feel deeply obligated to ensure patients can benefit from increased medication adherence, with the help of our technology. I am energised by our current conversations with our core customers and payor groups, and look forward to extending the reach and visibility of our work at ATS.”*

Learn more at [adherium.com](#)

This ASX announcement was approved and authorised for release by the Board of Adherium.



ASX Release

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Dr. Paul Mastoridis
Adherium Limited
Chief Executive Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at adherium.com